| P50 | author | Varda Rotter | Q16131089 |
| P2093 | author name string | Moshe Oren | |
| P2860 | cites work | Chemosensitivity linked to p73 function | Q73342473 |
| | Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants | Q73876727 |
| | Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery | Q77844569 |
| | Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy | Q77932308 |
| | p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 | Q79961068 |
| | Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells | Q79961179 |
| | p73 suppresses polyploidy and aneuploidy in the absence of functional p53 | Q80813940 |
| | Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 |
| | Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family | Q81662172 |
| | Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation | Q24301892 |
| | A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis | Q24312492 |
| | Mdm2 promotes the rapid degradation of p53 | Q24322597 |
| | The first 30 years of p53: growing ever more complex | Q24645732 |
| | Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II | Q24681272 |
| | Mutant p53 proteins bind DNA in a DNA structure-selective mode | Q24791476 |
| | Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene | Q28118453 |
| | A common polymorphism acts as an intragenic modifier of mutant p53 behaviour | Q28118809 |
| | Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 | Q28273002 |
| | TGFbeta in Cancer | Q28288866 |
| | Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis | Q28345092 |
| | TGF-beta signaling in tumor suppression and cancer progression | Q29615427 |
| | Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 |
| | Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 |
| | PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations | Q30416701 |
| | Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 |
| | TP53 mutations in human cancers: origins, consequences, and clinical use | Q33685392 |
| | A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity | Q33861971 |
| | Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. | Q33931140 |
| | The multistep nature of cancer | Q34366937 |
| | p53, p63 and p73--solos, alliances and feuds among family members | Q34515770 |
| | Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. | Q35207550 |
| | Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. | Q35804653 |
| | Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness | Q35839280 |
| | An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control | Q36065506 |
| | The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss | Q36649149 |
| | The oncogenic roles of p53 mutants in mouse models | Q36701574 |
| | Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment | Q36758893 |
| | TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes | Q36777326 |
| | Transcription regulation by mutant p53. | Q36777349 |
| | Mutant p53: an oncogenic transcription factor | Q36777355 |
| | Structural biology of the tumor suppressor p53 and cancer-associated mutants | Q36786022 |
| | Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways | Q36863902 |
| | Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations | Q37002268 |
| | Structural biology of the tumor suppressor p53. | Q37137883 |
| | Recent advances in p53 research: an interdisciplinary perspective. | Q37273304 |
| | When mutants gain new powers: news from the mutant p53 field. | Q37582777 |
| | p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells | Q37610416 |
| | p53 mutations: gains or losses? | Q37669027 |
| | Transcriptional regulation by p53. | Q37777267 |
| | Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. | Q38291171 |
| | Transactivation of the EGR1 gene contributes to mutant p53 gain of function | Q38334166 |
| | A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain | Q39458140 |
| | Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain | Q39575066 |
| | Tumor-derived p53 mutants induce NF-kappaB2 gene expression | Q39614332 |
| | p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug | Q39850223 |
| | PRIMA-1 reactivates mutant p53 by covalent binding to the core domain | Q39857551 |
| | Identification of GRO1 as a critical determinant for mutant p53 gain of function | Q39877618 |
| | Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. | Q39886632 |
| | The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs | Q39925932 |
| | Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. | Q39966300 |
| | Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. | Q40020159 |
| | Ubiquitination and degradation of mutant p53. | Q40073806 |
| | Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. | Q40100660 |
| | p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells | Q40106083 |
| | An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations | Q40198133 |
| | Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction | Q40208079 |
| | Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells | Q40281014 |
| | Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. | Q40401654 |
| | Modulation of gene expression by tumor-derived p53 mutants | Q40502644 |
| | Ser392 phosphorylation regulates the oncogenic function of mutant p53. | Q40534927 |
| | Cell type-specific regulation of calmodulin 2 expression by mutant p53. | Q40540649 |
| | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. | Q40568020 |
| | Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells | Q40642983 |
| | p53 increases experimental metastatic capacity of murine carcinoma cells | Q40649790 |
| | Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. | Q40649890 |
| | Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants | Q40755915 |
| | A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model | Q40845934 |
| | Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma | Q40860429 |
| | 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain | Q41023862 |
| | Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. | Q41203828 |
| | Gain of function mutations in p53. | Q41557652 |
| | Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. | Q41643433 |
| | Frequent p53 mutations in chemically induced murine fibrosarcoma | Q41666151 |
| | Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. | Q41762183 |
| | Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. | Q41808246 |
| | Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 |
| | Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants | Q42433750 |
| | Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice | Q42520917 |
| | Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis | Q43794889 |
| | Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. | Q43918911 |
| | Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins | Q44010460 |
| | Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination | Q45233764 |
| | p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. | Q46200576 |
| | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression | Q46709821 |
| | Differentiation plasticity regulated by TGF-beta family proteins in development and disease | Q46933819 |
| | Promyelocytic leukemia protein is required for gain of function by mutant p53. | Q47677481 |
| | Mutant p53 protein expression interferes with p53-independent apoptotic pathways | Q47775780 |
| | Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. | Q48030084 |
| | Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. | Q52561781 |
| | Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. | Q53385488 |
| | Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. | Q53551443 |
| | Mutant p53 gain of function: the NF-Y connection. | Q53600645 |
| | Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival | Q71381831 |
| | Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53 | Q73194052 |
| | Pharmacological rescue of mutant p53 conformation and function | Q73316566 |
| P433 | issue | 2 | |
| P304 | page(s) | a001107 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Biology | Q3927509 |
| P1476 | title | Mutant p53 gain-of-function in cancer | |
| P478 | volume | 2 | |